Friday, 23 December 2016

Global Pompe Disease Treatment Industry Will Grow Steadily At A CAGR Of 11.85% During The Period 2016-2020

Researchmoz added Most up-to-date research on "Global Pompe Disease Treatment Market 2016-2020" to its huge collection of research reports.

Lysosomal storage diseases (LSDs) are a group of progressive, autosomal recessive, and hereditary disorders characterized by the accumulation of specific substrates and variable age of onset and clinical symptoms. Pompe disease, a type of LSD, is caused by mutations in the GAA gene. These mutations inhibit the mechanism of action (MOA) of GAA; it is an enzyme responsible for catabolizing glycogen, resulting in accumulation of glycogen to toxic levels in the lysosomes of the cells. The buildup of glycogen in certain tissues and organs, especially in the muscles, hinders the normal functions of the organs. It can be further divided as adult-onset and infantile-onset Pompe diseases. As the disease is an autosomal recessive hereditary disorder, both parents are carriers and pass one copy of the mutated gene to their offspring. It affects both women and men across all ethnicities and races and has a varied age of onset of symptoms. Till date, researchers have identified over 300 genetic mutation types that lead to disease manifestation. Though there is no known cure for Pompe disease, enzyme replacement therapy (ERT) and diet therapy have been effective in reducing its clinical manifestations.

Technavios analysts forecast the global Pompe disease treatment market to grow at a CAGR of 11.85% during the period 2016-2020.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=902753

Covered in this report
The report covers the present scenario and the growth prospects of the global Pompe disease treatment market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of the drugs available in the market and the drug candidates that are in various phases of development for the treatment of Pompe disease.

The market is divided into the following segments based on geography:
Americas
APAC
EMEA

Technavio's report, Global Pompe Disease Treatment Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
Amicus Therapeutics
Audentes Therapeutics
Sanofi Genzyme

Other prominent vendors
EpiVax
Oxyrane
Sangamo BioSciences
Valerion Therapeutics

Market driver
Special regulatory drug designations for orphan drugs
For a full, detailed list, view our report

Market challenge
Limited patient population
For a full, detailed list, view our report

Market trend
Emergence of immunotherapy for Pompe disease
For a full, detailed list, view our report

Key questions answered in this report
What will the market size be in 2020 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=902753

No comments:

Post a Comment

Blood Thawing System Market Insights Shared in Detailed Report

Blood Thawing System Market: Introduction According to the report, the global  blood thawing system market  was valued at ~US$ 174 Mn in 2...